A specific inhibitor of mTOR activity
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Temsirolimus

Item No. 11590

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate] rapamycin
CAS Number
162635-04-3
Synonyms
  • CCI-779
  • Torisel®
Molecular Formula
C56H87NO16
Formula Weight
1030.3
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMF:PBS (pH 7.2) (1:4): 0.20 mg/mlDMSO: 12.5 mg/mlEthanol: 10 mg/ml
λmax
268, 277, 289 nm
SMILES
O=C(O[C@](CC([C@H](C)/C=C(C)/[C@@H](O)[C@@H](OC)C([C@@H](C1)C)=O)=O)([H])[C@H](C)C[C@@H]2CC[C@@H](OC(C(C)(CO)CO)=O)[C@H](OC)C2)[C@@]3([H])N(C(C([C@@]4(O)[C@H](C)CC[C@](C[C@@H](/C(C)=C/C=C/C=C\[C@H]1C)OC)([H])O4)=O)=O)CCCC3
InChi Code
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13-,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
InChi Key
CBPNZQVSJQDFBE-PXVOFZQNSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $63

    Add

    5 mg

    $107

    Add

    10 mg

    $203

    Add

    25 mg

    $345

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Temsirolimus is a dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin.1 Treatment with temsirolimus leads to cell cycle arrest in the G1 phase and also inhibition of tumor angiogenesis by reducing synthesis of VEGF.2,3 Temsirolimus demonstrates cytostatic activity in several xenograft models of human tumors in nude mice, including glioblastomas, prostate carcinoma, pancreatic, liver, and breast cancers, and medulloblastoma.2,4,3,1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dudkin, L., Dilling, M.B., Cheshire, P.J., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7, 1758-1764 (2001).

    2. Wan, X., Shen, N., Mendoza, A., et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 8(5), 394-401 (2006).

    3. Yu, K., Toral-Barza, L., Discafani, C., et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8(3), 249-258 (2001).

    4. Li, S., Liang, Y., Wu, M., et al. The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 13(1), (2013).